Maegim한국어

HLB생명과학

067630KOSDAQSector: Pharma & Biotech
₩2,045 2.85%Market cap ₩249.3BAs of Jul 21, 2026 close · updated once daily
D
Grade D31.5 ptsTop 84% of 2,523 stocks
Financial strength
27.8
Growth momentum
27.7
Price attractiveness
38.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

27.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
60.6%
Below median · Top 57.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
58.0%
Below median · Top 88.4% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-48.1%
Below median · Top 66.9% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-33.6%
Below median · Top 76.6% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

27.7
How much did revenue grow in a year?
Revenue growth (YoY)
-55.3%
Below median · Top 96.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-22.8%
Below median · Top 91.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
11.2%
Above median · Top 44.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-9.3%
Below median · Top 57.3% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

38.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 91.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.84x
Above median · Top 31.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15